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The rate of percutaneous renal artery intervention among
Medicare beneficiaries increased 2.4-fold in 2000 as
compared with 1996 on the premise that associated
hypertension and renal function would be cured.1 To date,
however recent randomized controlled trials (RCT) on
primary stenting for atherosclerotic renal artery stenosis
(ARAS) are not supporting evidence for its use.2 The goal of
this debate was to summarize the evidence on percuta-
neous renal artery stenting for ARAS.
The Clinical Problem
The reported incidence of atherosclerotic renal artery
stenosis (ARAS) in the Medicare population is 0.5% overall,3
but as these patients are often asymptomatic the true
frequency of ARAS is probably higher. ARAS is associated
with hypertension, chronic kidney disease and cardiac
disorders, although it is not clear whether these associa-
tions are causal.4 Nevertheless, patients with ARAS after
adjustment for other traditional risk factors, are at
increased risk for cardiovascular events with a risk of
coronary event that is increased by a factor of two and
markedly decreased survival.5 These outcomes are rare in
patients with ARAS that are treated medically6 and prob-
ably related to distribution and severity of atherosclerosis
in other vascular beds.7,8* Corresponding author. Tel.: þ33 (0) 5 49 44 38 46; fax: þ33 (0) 5
49 50 05 50.
E-mail address: jeanbaptistericco@gmail.com (J.-B. Ricco).Evaluation
ARAS is suspected in patients with the onset of hypertension
after 50 years of age. Confirmation of the diagnosis is made
by imaging. Doppler measurement of renal artery velocity
provides an assessment of the severity of the stenosis.
Alternative methods include MRA, computed tomographic
angiography (CTA) and digital subtraction angiography with
the use of small catheters and limited amounts of contrast
media. All these tests are useful in confirming the diagnosis
of ARAS, but Drieghe et al.9 have shown that even if renal
angiography and color duplex ultrasound correlate well,
both approaches tend to overestimate the ARAS severity
when compared with the measured trans-stenotic pressure
gradient using 0.014 pressure wires. Again none of these
techniques can establish the functional significance of ARAS.
Even the documentation of a trans-stenotic pressure
gradient in ARAS does not necessarily mean that the given
stenosis is the cause of hypertension.
Risk Factors and Medical Treatment
A major confounder related to the treatment of ARAS is
competing risk from other manifestations of atherosclerosis
including stroke, acute coronary syndrome, and congestive
heart failure. The risk of theseevents is greater than the risk of
complications related specifically to ARAS. They reflect
widespread atherosclerotic disease elsewhere.10 In this
context, medical therapy remains the cornerstone of treat-
ment for ARAS. Multi-drug regimens are needed for blood
pressure control including renin-angiotensin-aldosterone
inhibitor, alpha or beta-blocker, diuretic and calcium
channel antagonist. Thedemonstratedbenefitsof antiplatelet
therapy and statins in patients with atherosclerotic disease
also provide support for their use in patients with ARAS.
Prospective Randomized Controlled Trials
Benefit of renal stenting over angioplasty alone
Primary stenting of ARAS was compared to angioplasty
alone in one small RCT.11 The results of this trial were
comparable with those of a meta-analysis that compared
these two techniques.12 There was a 65% reduction in risk
of restenosis with stents at 6-months angiography but there
was no difference in blood pressure or renal outcome.
Primary stenting thus showed a more favorable outcome
with fewer reinterventions than angioplasty for ARAS.13
Benefit of renal artery stenting vs. surgery
Only one RCTcompared renal artery stenting vs. open surgical
revascularization in patients with ARAS.14 Inclusion criteria
were severe hypertension and ARAS >70%. There was no
significant difference in treatment outcome i.e. blood pres-
sure, renal outcome, mid-term patency and complications.
But as surgery was associated with a longer duration of
hospitalization (18 days vs. 10 days), the authors suggest that
renal artery stenting shouldbepreferred to surgery inpatients
who do not need concomitant aortic revascularization.
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the outcome of open surgical revascularization vs. endo-
vascular treatment showed that endovascular patency
declined by 0.26% permonth and that open revascularization
showed greater improvement for hypertension by 21% (95%
CI: 9e33%, pZ 0.001) and for renal function by 34% (95%CI:
18e54%, pZ 0.001) butwith a higher surgicalmortality, 3.1%
(95%CI: 1.8e4.4%, pZ 0.01) that became insignificant when
concomitant aortic surgery was excluded. Despite the
advantages of open revascularization, the attendant
morbidity and mortality of surgery ensures a significant role
for renal artery stenting inmost patients. However therewill
continue to be a role for open renal artery revascularization
in young patients with severe renal artery stenosis who are
more likely to benefit from the durability of renal bypasses.Comparison of renal artery stenting with medical
treatment alone
Comparison of renal artery stenting plus medical treatment
with medical treatment alone was available in three RCTs.
(Table 1). Two RCTs of limited power16,17 compared stent
placement with medical treatment in ARAS patients with
severe hypertension or recent impairment of renal func-
tion. These two studies did not show any significant
improvement in renal function, blood pressure outcome orTable 1 Randomized controlled trials comparing renal artery s
artery stenosis.
References Patients, No. Inclusion
criteria
Renal artery
stenosis
Rena
func
Ziakka
et al., 200816
36 with Stents
46 with MT
Hypertension 74% (mean) SCr:
2.3 m
STAR, 200917 64 with stents
76 with MT
Impaired
renal function
50% Crea
clea
< 80
min/
ASTRAL, 200918 403 with stents
403 with MT
Uncontrolled
hypertension
or unexplained
impaired
renal function
>50% GFR
min/
MT: Medical treatment alone, SCr: Serum creatinine, GFR: Glomerulasurvival in patients with renal stenting as compared with
medical treatment alone.
A larger trial, Angioplasty and Stenting for Renal Artery
Lesions (ASTRAL) furtherquestion thebenefitofARASstenting
vs. medical therapy alone.18 This RCT involved 806 patients
with ARAS. Patients were enrolled if clinical findings (recent
onset of hypertension or unexplained decreasing renal func-
tion) suggested a diagnosis of ARAS confirmed by duplex
echography, CTA or MRA in at least one renal artery and if the
physician was uncertain that the patient would benefit from
revascularization. ARAS severity was between 50 and 70%
diameter-reducing lesion in40%of thepatientsenrolled in the
trial and exceeded 70% in 60% of them. After 5-years, change
in renal function,mean systolic arterial pressure, and number
of cardiovascular events or death did not differ significantly
between the two groups. This result was confirmed in
a subgroup of patients with high-grade or bilateral ARAS.
Among patients with renal artery stenting, 4.2% suffered
procedure-relatedmajor complications including renal artery
rupture, dissection, thrombosis, embolization and worsening
of renal insufficiency (Table 1). The ASTRAL study concluded
that therewasnoadvantageof revascularization as compared
with medical treatment in patients with ARAS.
This trial was criticized because of its enrollment
strategy excluding patients who would likely benefit more
from renal stenting. In addition 40% of patients with renal
artery stenting had moderate renal artery stenosis betweententing with medical therapy alone for atherosclerotic renal
l
tion
Follow-up
(months)
Outcomes
g/dL
48 Renal function improved or stabilized
in 64% of patients with stents vs.
70% with medication alone. (NS)
Hypertension cured or improved
in 78% of patients with stents vs.
71.4% in the medical group. (NS)
tinine
rance
mL/
1.73 m2
24 No difference in renal event-free
survival (Hazard ratio: 0.73, 95%CI,
0.33e1.61].Procedure-related major
complications
2 procedure-related
deaths (3%)
1 late death duetoan infected hematoma
1 patient requested dialysisse-
condary to cholesterol embolism
: 40 mL/
1.73 m2
34 No difference in renal event-free
survival, GFR decline rate, blood
pressure, cardiovascular events
and survival.
Procedure-related major complications
(n Z 17, 4.2%):
5 kidney embolisms
4 renal artery occlusions
4 renal artery perforations
1 renal artery aneurysm
3 peripheral embolisms (amputations)
r filtration rate, NS: not significant.
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limited benefit from revascularization could be expected.
Pressure gradient across the stenosis was not measured in
this study and there was no core laboratory to validate the
on-site visual estimates of ARAS. There were also significant
crossovers in this study with only 359 of 403 patients
randomized to renal artery stenting who underwent the
procedure while 24 of 403 patients assigned to medical
treatment underwent intervention. But when examined on
a per-protocol analysis, there was still no apparent benefit
for renal artery stenting.
Randomized Controlled Trials: What Have We
Learned?
The results of these three RCTs need to be considered
carefully in light of their design. The enrollment strategy of
the ASTRAL trial regarding the doubt of the effectiveness of
revascularization meant that clinicians were uncertain as to
whether they should intervene; consequently they consid-
ered the randomization to be appropriate. Despite some
criticisms almost all patients enrolled in these RCTs would
have been considered for renal artery stenting in normal
clinical practice. In the ASTRAL trial, the skills of the
physicians performing renal stenting were not formally
assessed but their expertise was reflected in a technical
success rate of 95% and the rate of serious complications
was similar to that of other methodologically solid studies
with rigorous recording keeping. In summary, these trials
provide evidence that in typical patients considered for
renal revascularization in today current clinical practice,
intervention offers no clinical benefit and has some risk as
compared to best medical treatment alone. It is possible
however that renal artery stenting might benefit a minority
of patients with specific clinical presentations that were
not specifically addressed in these RCTs.
Ongoing Trials
Following the ASTRAL study, three ongoing RCT’s were
designed to better assess renal and cardiac outcomes after
renal artery stenting. The Renal Atherosclerotic Revascu-
larization (RAVE) compares renal stenting with best medical
treatment alone with a composite end-point that includes
death, dialysis, and doubling of serum creatinine.19 The
RADAR study compares best medical treatment with bestTable 2 Reasons for skepticism regarding renal artery stenting
1. Failure to define causal role of atherosclerotic renal artery ste
hypertension or worsened renal function.
2. Imprecise definition of ARAS with inclusion of subcritical ARAS
renal hemodynamics.
3. Compensatory action of the non-stenotic kidney.
4. Advances in medical management: Blockade of the renin-angio
drugs, antiplatelet agents and statins.
5. Complications of ARAS stenting: Kidney embolism, occlusion, p
contrast nephropathy.
6. Negative outcomes from randomized controlled trials.medical treatment plus renal artery stenting in patients
with hemodynamically relevant atherosclerotic renal artery
stenosis. The primary end-point being the change in esti-
mated glomerular filtration rate between the two groups
during 12-months follow-up. Secondary end-points included
technical success; change in average blood pressure and in
left ventricular mass index. Finally the CORAL trial20
compares best medical treatment alone with renal stent-
ing on a composite heart, vascular and renal end-point. In
this trial, angiography and transluminal pressure gradients
were used to determine entry in the study with a core
laboratory using quantitative analysis. Patients with
a gradient 20 mm Hg and a renal artery >35 mm in
diameter were considered for randomization.
Technical Issues Related to ARAS Stenting
Renal artery stenting has improved over recent years with
small-platform including less traumatic pre-mounted low
profile stent on 0.014 or 0.018 inchwire, less traumatic 2.5 to
4-Fr shaft balloons, steerable catheters, smaller puncture
site and rapid exchange systems avoiding need for long
wires. Despite these significant improvements, ARAS stent-
ing is not an easy procedure and atheroembolic disease
remains a major concern with manipulation of the renal
artery, which is a predictor of embolic events.21 Distal
embolic protection devices have been logically used to avoid
this complication. But in an RCT, Cooper et al.22 showed
a decline in estimated glomerular filtration rate in both
groups of patientswith andwithout protection device. In this
series, the only group with no loss of glomerular filtration
was receiving both the embolic protection device and
a platelet glycoprotein inhibitor (abciximab) suggesting
a risk of intra-arterial thrombosis triggered by the use of the
embolic protection device.
Refining the Approach to Renal Artery
Revascularization
As renal artery stenting falls short in these RCTs, many
nephrologists have moved toward a more conservative
approach concerning ARAS (Table 2) probably also to
counterbalance the attitude of aggressive cardiologists and
radiologists.23 Despite the difficulty in demonstrating
benefits of renal artery stenting in large groups that
included heterogeneous populations with a mixture of high.
nosis (ARAS) in disease syndromes such as
in trials and lack of methods to assess
tensin system, effective anti-hypertensive
erforation or dissection of the renal artery,
142 F. Schneider, J.-B. Riccoand low risk patients, pathophysiological rationale and the
positive results of some small series have provided valid
arguments for renal stenting in a few ARAS patients with
deteriorating renal function after receiving ACE inhibitors
or angiotensin-receptors blockers and in patients with flash
edema or uncontrolled heart failure.24,25 In addition, many
physicians recognize that some patients with severe
stenosis particularly affecting both renal arteries or a soli-
tary kidney should be considered as potential candidates
for renal artery stenting26 even if the ASTRAL study showed
no difference in outcome between renal artery lesions of
varying severity.Conclusions
Recent evidence shows that optimal medical treatment
including statins and risk reduction factors should be the
preferred option for most patients with ARAS. It is almost
certain that the vast majority of typical patients now being
subjected to renal artery stenting show no added benefits
regarding blood pressure and kidney function as compared
to best medical treatment alone. But it is equally important
to recognize that a minority of patients with rapidly
progressive hypertension or renal insufficiency and flash
pulmonary edema or with specific lesions such as bilateral
severe renal artery stenosis or solitary kidney do have
a benefit from restoring kidney perfusion.References
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It was expected that information resulting from recently
completed randomized controlled trials would clarify
the role of renal artery interventions in patients with
atherosclerotic renal artery stenoses. Unfortunately, in this
respect, we were left disappointed. Concerns regarding* Corresponding author. J.-B. Ricco, University Hospital Jean
Bernard, Department of Vascular Surgery, 86021 Poitiers, France.
Tel.: þ33 (0) 5 49 44 38 46; fax: þ33 (0) 5 49 50 05 50.
E-mail address: jeanbaptistericco@gmail.com (J.-B. Ricco).such issues as inclusion criteria limited the validity of these
studies’ conclusions leaving a persistent knowledge gap
into which our debators step.
Although the authors were given separate charges, their
conclusions are more similar, than different. They both
recognize the need for further study and information to
elucidate the role of renal artery interventions. They
recognize that we currently cannot accurately predict the
natural history of any individual renal artery lesion, nor
recognize entirely which lesions are responsible for
a patient’s hypertension or renal insufficiency. So instead of
recommending whether the majority, or the minority of
patients should be intervened upon, they appropriately
meet somewhere in the middle.
With the present uncertainty the authors propose
a multidisciplinary, collaborative approach to these often
complicated clinical situations to arrive at decisions
regarding individual patients. They propose a more
aggressive approach in patients with specific criteria,
including progressive hypertension, renal insufficiency with
flash pulmonary edema, bilateral severe renal artery
stenoses, and stenoses with a solitary kidney. Until further
information is hopefully obtained from ongoing trials, this
selective approach seems reasonable and most prudent.
doi: 10.1016/j.ejvs.2011.06.004
